Abbvi today
From 13:59 on East
- 52-week range
- $ 153.58
▼
$ 218.66
- Dividend profitability
- 3.53%
- P/e ratio.
- 77.48
- Value is valuable
- $ 211.19
If you were or think about getting to abbvie NYSE: ABBVThere is still time to do it. ABBVIE shares price is in Stable upward trend And over time it will set new records for the whole time. The reason that is simple: it is an incredibly well -controlled company with a foresaw management that positioned it for success.
After relying on Humira for income, margins and profit, now it is a well -diversified pharmaceutical company with a cap filled with blockbusters. A critical conclusion is that he, like his parent, Abbott Laboratories, is a healthy car returning capital on the right track to pay significant dividends when buying shares and maintaining the position of the fortress.
ABBVIE releases a signal dedicated to the trend after the release and update of the Q1 manual
The ABBVIE price is fixed to the long -term trend line at the beginning of 2025 and released the signal followed by the trend after the release of FQ1. The company’s results prove its success and prospects, and income increased by 8.4%, which was ahead of the Marketbeat consensus, reported by more than 300 basic points. The force was noticed in most segments, led by an increase in immunology by 16.6%.
Immunology is the main segment and includes Humira sales, which fell 50% compared to last year. Nevertheless, the weakness in Humir was compensated by the force in the new drugs sold, Skyrizi and Rinvoq, which increased by 72% and 57.2%, respectively.
They made up 38% of the network and, as expected, will remain strong in the foreseeable future. Neurobiology was also strong with an increase of 16.1%, which was followed by an increase in oncology by 5.8%and a decrease in aesthetics by 11.7%.
The company experienced margin pressure, primarily in the form of adverse IPR & D. Silver lining is that an increase in IPR & D is associated with the positive developments of the pipeline, which help to ensure the long -term growth of the company. Despite this, the influence was less than expected, leaving the adjusted EPS at the level of $ 2.46, increased by 6.5% compared to the same period last year (YOY) and by 0.06 US dollars better than the forecast.
More importantly, the leadership was improved, which aligned the adjusted EPS target range with analysts to an 20 percent increase compared to last year.
Analysting trends are pushing the ABBVIE market towards all maximums
Dividend payments ABBVIE
- Dividend profitability
- 3.50%
- Annual dividend
- $ 6.56
- Dividend increases the track record
- 53 years
- Annual growth of dividends 3-year
- 6.04%
- Dividend payment coefficient
- 273.33%
- The next payment of dividends
- Maybe. 15
The history of dividends ABBV
As the bear appears, how the price correction for shares of 2025 appears, the trends of analysts contradict this. These include a significantly increased coating since last year, strengthening moods with high conviction of a moderate purchase and an increased target price of consensus.
The consensus at the end of April 2025 increased by almost 20% per year, and many changes in H1 led to a high -class range. These trends are not expected to change and can gain impulse after updating the leadership.
Analysts and institutions similar to this action for the return of capital. It is expected that the company will pay 3% of its income in 2025 and annually grow distribution. Abbvie is a technical dividend aristocrat And King, due to stable 5-year relations with Ebbott, is on the way to continuing the distribution annually for many years. ABBVIE also redeems shares, but only enough to compensate for dilution from compensation based on shares.
Abbvie released a trend after a signal in April
Abbvi Price correction in early April reached the bottom And he soon confirmed his ascending trend. The price action after release Q1 corresponds to the signal, increasing by 3.5% in the preliminary action. The market can easily rise to re -check its record until the middle of the year in this scenario, suggesting that it follows by signal. If not, then the price of ABBVIE shares can remain in the range until the late year, with the potential for a share in the range from 200 to $ 220.
Before considering ABBVIE, you will want to hear it.
Marketbeat monitors the highest and most effective analysts with the most effective Wall Street analysts and promotions that they recommend to their customers daily. Marketbeat has identified five shares that leading analysts quietly whisper to their clients to buy now before the wider market conquers … And Abbvi was not on the list.
While Abbvie is currently having an average purchase rating among analysts, analysts with the highest rating believe that these five promotions are better buying.
View five shares here
Want to know what will be the following actions that will be large, with solid grounds? Enter your email address to see which MarketBeat analysts can become the following blockbuster growth promotions.
Get this free report